{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:51Z","timestamp":1792900131389,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hereditary hemorrhagic telangiectasia (HHT) is characterized by arteriovenous malformations and telangiectasia, with primary clinical manifestations of epistaxis and gastrointestinal bleeding and resultant anemia. HHT negatively affects health-related quality of life (HR-QoL); however, existing tools to measure HR-QoL are not HHT specific. Our objective was to develop an HHT-specific HR-QoL (HHT-QoL) instrument and evaluate its performance in a cross-sectional survey of individuals with HHT. Four HHT-specific questions were developed to evaluate the impact of HHT on productivity and social and personal interactions. An anonymous e-mail survey was conducted through Cure HHT. Participants also indicated their perceived HHT severity and completed 3 Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires: Discretionary Social Activities, Social Roles, and Emotional Distress. Complete data were available for 290 participants who self-identified their HHT severity as mild (29%), moderate (46%), or severe (25%). The HHT-QoL scale was reliable (Cronbach\u2019s-\u03b1, 0.83). Principal components analysis indicated the instrument was unidimensional. Participants had low levels of QoL with their ability to participate in discretionary social activities (PROMIS mean 36.4 [standard deviation 14.3]) and perform in social roles (41.5 [17.2]), and the presence of a high level of emotional distress (64.8 [24.2]). The HHT-QoL score correlated negatively with PROMIS Discretionary Social Activities (r = \u22120.65) and Social Roles (r = \u22120.68) and positively correlated with PROMIS Emotional Distress (r = 0.51). In conclusion, the 4-item HHT-QoL instrument provides valuable insight and may be a useful addition to future clinical research in HHT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007748","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:35:29Z","timestamp":1658504129000},"page":"4301-4309","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-3082","authenticated-orcid":false,"given":"Raj S.","family":"Kasthuri","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-5627","authenticated-orcid":false,"given":"Sonia","family":"Thomas","sequence":"additional","affiliation":[{"name":"3RTI International, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Vandergrift","sequence":"additional","affiliation":[{"name":"3RTI International, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-8305","authenticated-orcid":false,"given":"Carla","family":"Bann","sequence":"additional","affiliation":[{"name":"3RTI International, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schaefer","sequence":"additional","affiliation":[{"name":"4Cure HHT Foundation, Monkton, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S.","family":"Clancy","sequence":"additional","affiliation":[{"name":"4Cure HHT Foundation, Monkton, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Pyeritz","sequence":"additional","affiliation":[{"name":"5Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-475X","authenticated-orcid":false,"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"6Taussig Cancer Institute, and"},{"name":"7Department of Metabolic and Cardiovascular Sciences, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"7","key":"2022072215351516500_B1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/GIM.0b013e3182136d32","article-title":"Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis","volume":"13","author":"McDonald","year":"2011","journal-title":"Genet Med."},{"issue":"7","key":"2022072215351516500_B2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1538-7836.2010.03860.x","article-title":"Hereditary hemorrhagic telangiectasia: from molecular biology to patient care","volume":"8","author":"Dupuis-Girod","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"8","key":"2022072215351516500_B3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/jmg.29.8.527","article-title":"Hereditary haemorrhagic telangiectasia: a clinical analysis","volume":"29","author":"Porteous","year":"1992","journal-title":"J Med Genet."},{"issue":"10","key":"2022072215351516500_B4","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","volume":"92","author":"Kasthuri","year":"2017","journal-title":"Am J Hematol."},{"issue":"1","key":"2022072215351516500_B5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12687-015-0254-0","article-title":"Life experiences of individuals with hereditary hemorrhagic telangiectasia and disclosing outside the family: a qualitative analysis","volume":"7","author":"Higa","year":"2016","journal-title":"J Community Genet."},{"key":"2022072215351516500_B6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey","volume":"153","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res."},{"issue":"5","key":"2022072215351516500_B7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.otohns.2006.12.019","article-title":"Health-related quality of life in hereditary hemorrhagic telangiectasia","volume":"136","author":"Geisthoff","year":"2007","journal-title":"Otolaryngol Head Neck Surg."},{"issue":"6","key":"2022072215351516500_B8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ajmg.a.35309","article-title":"Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study","volume":"158A","author":"Geirdal","year":"2012","journal-title":"Am J Med Genet A."},{"issue":"1","key":"2022072215351516500_B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/194589240501900112","article-title":"The SF-36 health status questionnaire in assessing patients with epistaxis secondary to hereditary hemorrhagic telangiectasia","volume":"19","author":"Lennox","year":"2005","journal-title":"Am J Rhinol."},{"issue":"10","key":"2022072215351516500_B10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11136-004-7865-y","article-title":"Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease","volume":"13","author":"Pasculli","year":"2004","journal-title":"Qual Life Res."},{"issue":"1","key":"2022072215351516500_B11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA."},{"issue":"6724","key":"2022072215351516500_B12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/bmj.300.6724.573","article-title":"Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis","volume":"300","author":"Canadian Erythropoietin Study Group","year":"1990","journal-title":"BMJ."},{"issue":"26","key":"2022072215351516500_B13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","article-title":"The effects of antihypertensive therapy on the quality of life","volume":"314","author":"Croog","year":"1986","journal-title":"N Engl J Med."},{"issue":"11","key":"2022072215351516500_B14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/alr.21374","article-title":"The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"4","author":"Merlo","year":"2014","journal-title":"Int Forum Allergy Rhinol."},{"issue":"1","key":"2022072215351516500_B15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2018.2018.0190","article-title":"Thalidomide for the management of bleeding episodes in patients with hereditary hemorrhagic telangiectasia, effects on epistaxis severity score and quality of life","volume":"36","author":"Baysal","year":"2019","journal-title":"Turk J Haematol."},{"issue":"1","key":"2022072215351516500_B16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0895-4356(02)00537-1","article-title":"Comparative responsiveness of generic and specific quality-of-life instruments","volume":"56","author":"Wiebe","year":"2003","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2022072215351516500_B17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia [published correction appears in Laryngoscope. 2021;131(12)2834]","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope."},{"issue":"5","key":"2022072215351516500_B18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.outlook.2014.05.009","article-title":"Patient-Reported Outcomes Measurement Information System (PROMIS): efficient, standardized tools to measure self-reported health and quality of life","volume":"62","author":"Bevans","year":"2014","journal-title":"Nurs Outlook."},{"issue":"5","key":"2022072215351516500_B19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/hea0000741","article-title":"PROMIS\u00ae: Standardizing the patient voice in health psychology research and practice","volume":"38","author":"Yount","year":"2019","journal-title":"Health Psychol."},{"issue":"5","key":"2022072215351516500_B20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1037\/hea0000752","article-title":"Beyond methods to applied research: realizing the vision of PROMIS\u00ae","volume":"38","author":"Smith","year":"2019","journal-title":"Health Psychol."},{"key":"2022072215351516500_B21","author":"HealthMeasures.net"},{"key":"2022072215351516500_B22","author":"HealthMeasures.net"},{"key":"2022072215351516500_B23","author":"HealthMeasures.net"},{"key":"2022072215351516500_B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5116\/ijme.4dfb.8dfd","article-title":"Making sense of Cronbach\u2019s alpha","volume":"2","author":"Tavakol","year":"2011","journal-title":"Int J Med Educ."},{"key":"2022072215351516500_B25","first-page":"248","article-title":"The assessment of reliability","volume":"3","author":"Nunnally","year":"1994","journal-title":"Psychometric Theory."},{"key":"2022072215351516500_B26","doi-asserted-by":"crossref","DOI":"10.1002\/0471725331","volume-title":"A User\u2019s Guide to Principal Component Analysis.","author":"Jackson","year":"1991"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4301\/1909517\/advancesadv2022007748.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4301\/1909517\/advancesadv2022007748.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:35:54Z","timestamp":1658504154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4301\/485436\/Development-and-performance-of-a-hereditary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007748","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}